Dongqian Yang , Xiaohua Liu , Jing Li , Kaijuan Wu , Jing Xie , Yixiao Wang , Zheng Wang , Liping Jiang
{"title":"Anti-Toxoplasma gondii studies of the venom peptide XYP4 from the Lycosa coelestis","authors":"Dongqian Yang , Xiaohua Liu , Jing Li , Kaijuan Wu , Jing Xie , Yixiao Wang , Zheng Wang , Liping Jiang","doi":"10.1016/j.toxicon.2025.108540","DOIUrl":null,"url":null,"abstract":"<div><div><em>Toxoplasma gondii</em> (<em>T. gondii</em>) is an intracellular parasite with multiple routes of infection that poses a serious health risk to pregnant women, fetuses, and immunocompromised populations. Currently, clinical drugs in the treatment of toxoplasmosis continue to face challenges such as drug resistance. In the face of this challenge, researchers have gradually focused on the potential medicinal value of animal venoms in the fight against <em>T. gondii</em>, especially venom peptides showing advantages such as high potency, membrane targeting, and immunomodulation. The present study aimed to explore whether XYP4, a peptide derived from the venom of the <em>Lycosa coelestis</em> (<em>L. coelestis</em>), possesses better anti-<em>T. gondii</em> activity and its mode of action. The experimental results showed that XYP4 is an amphiphilic cationic linear polypeptide with an α-helix, which can exert anti-<em>toxoplasma</em> activity at low concentrations, affecting the lytic cycle. This polypeptide showed moderate survival benefits in mice infected with <em>T. gondii</em>. The main modes of action of XYP4 include inhibition of tachyzoites' intracellular proliferation, modulation of inflammatory factor expression in the host cells, and disruption of tachyzoite membrane integrity.</div></div>","PeriodicalId":23289,"journal":{"name":"Toxicon","volume":"266 ","pages":"Article 108540"},"PeriodicalIF":2.4000,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Toxicon","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0041010125003150","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Toxoplasma gondii (T. gondii) is an intracellular parasite with multiple routes of infection that poses a serious health risk to pregnant women, fetuses, and immunocompromised populations. Currently, clinical drugs in the treatment of toxoplasmosis continue to face challenges such as drug resistance. In the face of this challenge, researchers have gradually focused on the potential medicinal value of animal venoms in the fight against T. gondii, especially venom peptides showing advantages such as high potency, membrane targeting, and immunomodulation. The present study aimed to explore whether XYP4, a peptide derived from the venom of the Lycosa coelestis (L. coelestis), possesses better anti-T. gondii activity and its mode of action. The experimental results showed that XYP4 is an amphiphilic cationic linear polypeptide with an α-helix, which can exert anti-toxoplasma activity at low concentrations, affecting the lytic cycle. This polypeptide showed moderate survival benefits in mice infected with T. gondii. The main modes of action of XYP4 include inhibition of tachyzoites' intracellular proliferation, modulation of inflammatory factor expression in the host cells, and disruption of tachyzoite membrane integrity.
期刊介绍:
Toxicon has an open access mirror Toxicon: X, sharing the same aims and scope, editorial team, submission system and rigorous peer review. An introductory offer Toxicon: X - full waiver of the Open Access fee.
Toxicon''s "aims and scope" are to publish:
-articles containing the results of original research on problems related to toxins derived from animals, plants and microorganisms
-papers on novel findings related to the chemical, pharmacological, toxicological, and immunological properties of natural toxins
-molecular biological studies of toxins and other genes from poisonous and venomous organisms that advance understanding of the role or function of toxins
-clinical observations on poisoning and envenoming where a new therapeutic principle has been proposed or a decidedly superior clinical result has been obtained.
-material on the use of toxins as tools in studying biological processes and material on subjects related to venom and antivenom problems.
-articles on the translational application of toxins, for example as drugs and insecticides
-epidemiological studies on envenoming or poisoning, so long as they highlight a previously unrecognised medical problem or provide insight into the prevention or medical treatment of envenoming or poisoning. Retrospective surveys of hospital records, especially those lacking species identification, will not be considered for publication. Properly designed prospective community-based surveys are strongly encouraged.
-articles describing well-known activities of venoms, such as antibacterial, anticancer, and analgesic activities of arachnid venoms, without any attempt to define the mechanism of action or purify the active component, will not be considered for publication in Toxicon.
-review articles on problems related to toxinology.
To encourage the exchange of ideas, sections of the journal may be devoted to Short Communications, Letters to the Editor and activities of the affiliated societies.